Eli Lilly and Company $LLY Stake Increased by Money Concepts Capital Corp

Money Concepts Capital Corp increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 2.7% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 14,218 shares of the company’s stock after purchasing an additional 377 shares during the quarter. Eli Lilly and Company accounts for about 0.7% of Money Concepts Capital Corp’s investment portfolio, making the stock its 23rd largest holding. Money Concepts Capital Corp’s holdings in Eli Lilly and Company were worth $16,452,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Bank of America Corp DE acquired a new position in Eli Lilly and Company during the second quarter valued at approximately $13,522,666,000. Jupiter Topco LLC acquired a new stake in shares of Eli Lilly and Company in the second quarter worth $4,667,180,000. Corient Private Wealth LP acquired a new stake in shares of Eli Lilly and Company in the second quarter worth $764,116,000. BlackRock Inc. increased its position in shares of Eli Lilly and Company by 1.6% in the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock worth $81,009,981,000 after acquiring an additional 1,046,558 shares in the last quarter. Finally, State Street Corp raised its stake in shares of Eli Lilly and Company by 1.7% in the 2nd quarter. State Street Corp now owns 36,215,754 shares of the company’s stock valued at $43,438,262,000 after acquiring an additional 605,752 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 0.3%

NYSE LLY opened at $1,433.34 on Friday. The stock has a market cap of $1.35 trillion, a PE ratio of 46.52, a P/E/G ratio of 1.72 and a beta of 0.40. Eli Lilly and Company has a fifty-two week low of $850.51 and a fifty-two week high of $1,460.00. The business has a 50 day moving average price of $1,236.58 and a two-hundred day moving average price of $1,108.27. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.71 by $1.77. The company had revenue of $24.40 billion for the quarter, compared to analyst estimates of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The business’s quarterly revenue was up 38.6% on a year-over-year basis. During the same quarter last year, the firm posted $7.02 earnings per share. As a group, sell-side analysts predict that Eli Lilly and Company will post 35.70 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a $1.73 dividend. The ex-dividend date is Friday, November 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. Eli Lilly and Company’s dividend payout ratio is 22.46%.

Insiders Place Their Bets

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the business’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the transaction, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. The trade was a 10.72% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the transaction, the executive vice president directly owned 4,137 shares of the company’s stock, valued at approximately $5,802,225.24. The trade was a 54.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is currently owned by company insiders.

Trending Headlines about Eli Lilly and Company

These are some of the LLY headlines that stood out recently:

• Positive Sentiment: Lilly broke ground on a $3.5 billion Pennsylvania facility to make injectable medicines, including next-generation candidate retatrutide. The investment could expand manufacturing capacity for future demand and is expected to create 850 permanent jobs, though the benefits will take time to materialize. Lilly facility announcement
• Positive Sentiment: A Phase 3b study found that combining Zepbound with Taltz improved and sustained outcomes in adults with psoriatic arthritis and obesity compared with Taltz alone. The results could support broader use of Lilly’s medicines in patients with both conditions. Phase 3b study announcement
• Neutral Sentiment: Lilly’s obesity collaboration with Fauna Bio designated a second discovery target using AI-based research. It adds to the early-stage pipeline, but any commercial impact is uncertain and likely years away. Fauna Bio announcement

Wall Street Analysts Forecast Growth

LLY has been the topic of several recent research reports. UBS Group lifted their target price on shares of Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the company a “buy” rating in a report on Friday, October 30th. Argus upped their price target on shares of Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the stock a “buy” rating in a research report on Friday, October 30th. JPMorgan Chase & Co. increased their price target on Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the company an “overweight” rating in a report on Friday, October 30th. HSBC raised their price objective on Eli Lilly and Company from $850.00 to $940.00 and gave the company a “reduce” rating in a research report on Thursday, September 10th. Finally, Bank of America reissued a “buy” rating and issued a $1,497.00 price objective on shares of Eli Lilly and Company in a research report on Friday, October 30th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $1,416.64.

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.